Camurati-Engelmann Disease (CED) is a rare, autosomal dominantly inherited bone dysplasia. This review is based on the unpublished and detailed clinical, radiological and molecular findings in 14 CED families -comprising 41 patients -combined with data from ten other CED families previously described in the literature. For all patients (100 in total), molecular evidence for CED was provided as a mutation in TGFB1, the gene encoding transforming growth factor (TGF)-β1, was detected. Evaluation of these 24 CED families shows pain in the extremities to be the most common clinical symptom, present in 68% of the patients. A waddling gait (48%), easy fatigability (44%) and muscle weakness (39%) are also present at a high prevalence in this patient set. Radiological symptoms are not fully penetrant, with 94% of the investigated patients showing the typical long bone involvement. A large percentage of the patients investigated additionally shows affection of the skull (54%) and pelvis (63%). The review provides the reader with an overview of possible treatments, diagnostic guidelines and considerations for prenatal testing. The detailed description of such a large set of CED patients will be of great help to clinicians in establishing a correct diagnosis, in genetic counselling and treatment.
INTRODUCTION
Camurati-Engelmann Disease (CED) or Progressive Diaphyseal Dysplasia (MIM 131300) is an autosomal dominant condition belonging to the group of craniotubular hyperostoses. Initially described by Cockayne in 1920 [1] , Camurati was the first to suggest its hereditary nature in 1922. [2] In 1929, Engelmann reported a single case with muscular wasting and marked bone involvement. [3] The name Progressive Diaphyseal Dysplasia emphasises the progressive nature of the hyperostosis and the ever-present affection of the diaphyses [4] , but currently, the eponym Camurati-Engelmann Disease is widely accepted.
The hallmark of the disorder is the cortical thickening of the diaphyses of the long bones. Hyperostosis is bilateral and symmetrical and usually starts at the diaphyses of the femora and tibiae, expanding to the fibulae, humeri, ulnae and radii. As the disease progresses, the metaphyses may become affected as well, but the epiphyses are spared. [5] Sclerotic changes at the skull base may be present. The onset of the disease is usually during childhood and almost always before the age of 30. Most patients present with limb pain, muscular weakness, a waddling gait and easy fatigability. Systemic manifestations, such as anemia, leukopenia and hepatosplenomegaly occur occasionally. [6] Abnormal values for several markers of bone formation and resorption have been reported in a few patients. [7] [8] In this review, clinical, radiological and molecular data on 24 CED families were collected. Presentation of families from Europe, Asia, Africa, America, Australia and Oceania illustrates that CED is spread worldwide. 14 of the families (42 patients) were examined by at least one of the authors. Data on ten additional families (59 patients) were collected from the literature. [9] [10] [11] [12] Including the families presented in this paper, TGFB1 mutations in 45 CED families have been described worldwide. [ Table 2 and Figure 5 ). The absence of a mutation in a family described by Hecht et al. [15] raises the possibility of genetic heterogeneity in this disorder. This is further suggested by the absence of mutations in the coding region of TGFB1 in several isolated patients and small families investigated in our laboratory (unpublished data). However, the disease in the latter families might be caused by a mutation in a non-coding position of TGFB1, affecting mRNA stability, protein expression level, transcription factor binding, … The possibility that CED is not the underlying disorder in these families should also not be overlooked: in a substantial subset of our patients lacking a TGFB1 mutation, we found indications that the diagnosis was incorrect (either through atypical radiological, clinical or biochemical symptoms or because of a different inheritance pattern). Thusfar, we were not able to find convincing evidence for genetic heterogeneity in our set of cases and families. Table 2 .
TGF-β1 is formed as a pro-precursor molecule, consisting of the signal peptide, the latency-associated peptide and the mature peptide. Posttranslational processing yields the small latent complex, a non-covalent association between two latency-associated peptides and two mature peptides. The majority (7/10) of the mutations detected in CED are missense mutations located in exon 4 -coding for the region in the latency-associated peptide surrounding the residues responsible for homodimerisation (Cys223 and Cys225) -making up 82.2% of all mutations reported so far. The arginine residue at position 218 is a mutation hotspot, representing 60% of the mutations. Mutations outside exon 4 include a nine basepair duplication in the part of exon 1 encoding the signal peptide and two missense mutations in exon 1 and exon 2, at the N-terminus of the latency-associated peptide.
Functionally, the CED mutations have been classified into two groups.
[17] Exon 4 mutations destabilise disulphide bridging of the latency-associated peptides, causing premature activation of the mature peptide. Exon 1 mutations rather affect secretion, leading to intracellular retention of the mutant protein. All mutations investigated so far increase TGF-β1 activity. [17] [21] In CED patients, the narrowing of the medullar cavity at the endosteal side and the modelling defect at the periosteal side of the diaphyses of the long bones suggest that both the osteoclastic resorption capacity and the osteoblastic bone formation are disturbed. This observation is in line with the presumed action of the mutant protein, as TGF-β1 has been shown to stimulate bone formation and suppress bone resorption under physiological circumstances. [22] Most clinical features of CED, such as bone pain in the limbs, waddling gait and auditory impairment, are secondary to the hyperostosis and sclerosis of the skeleton.
However, the reduction in fat and muscle mass, observed in a significant percentage of the patients (21% and 39% respectively in this population), seems to be unrelated to the affection of the skeleton. We sought to clarify these additional symptoms based on the mutations detected. TGF-β1 is a known inhibitor of myogenesis, impairing fusion of myoblasts into multinucleated myotubes. [23] Indeed, recent evidence points to a role for the TGF-β pathway in repressing the expression of two important myogenic transcription factors. [24] TGF-β1 also inhibits adipogenesis [25] , at least partly through the transcriptional repression of genes important in adipocyte differentiation. [26] An increased TGF-β1 activity as seen in CED patients (see further) is therefore expected to inhibit muscle and fat development. It is of note that dexamethasone, a synthetic glucocorticoid and a known stimulator of adipogenesis, was recently shown to reverse TGF-β-mediated inhibition of preadipocyte differentiation. [27] How can it be explained that activating mutations in a protein like TGF-β1, whose receptors are ubiquitously expressed [28] , cause the relatively mild CED phenotype? One possible explanation is the presence of modifier genes that modulate the outcome of the principal mutation (see above). However, to our opinion this is insufficient to account for the absence of symptoms during embryonic development, in which TGF-β1 was shown to play a critical role [29] [30] [31] or in tissues like heart, pancreas, kidney, lung and skin, where TGF-β1 is highly expressed during adult life. [32] [33] We propose the following hypothesis. TGF-β1 is posttranslationally processed to a non-covalent small latent complex of the mature peptide and latency-associated peptide. In most tissues, this complex covalently associates with a latency-associated TGF-β binding protein to form a high-molecular weight latent complex (large latent complex) that is directed for storage in the extracellular matrix. [34] However, bone forms an exception as bone cells produce predominantly the small latent complex [35] [36] [37] , a form suggested to represent a pool of readily available TGF-β1, necessary in an environment where TGF-β1 plays such an important role throughout life. [37] We raise the possibility that the capacity of a mutation to alter the structure of the latent complex depends on the presence of the latency-associated TGF-β binding protein. Following this view, conformational changes needed for premature activation of the mature peptide are quenched in the large latent complex. However, when secreted as the small latent complex, the latency-associated peptide alters its conformation under the influence of the mutation, releasing some of the mature peptide or at least facilitating its activation. Experiments are underway to confirm/reject this hypothesis.
Treatment
Glucocorticosteroids are anti-inflammatory and immunosuppressive agents. In bone, they exert the unfavourable side effect of decreasing bone density 1) by increasing the apoptosis rate of osteoblasts and osteocytes while suppressing osteoblast proliferation, differentiation and bone matrix synthesis [38] [39]; 2) by enhancing proliferation and differentiation of osteoclast precursors [40] [41] and 3) by decreasing intestinal calcium absorption. [42] In CED patients, this 'side effect' is turned into an advantage: glucocorticoids are applied to counteract the increased bone formation. Moreover, they exert a direct effect on TGF-β expression, activation and signalling, although the exact mechanism needs further clarification. On the one hand, glucocorticoids are seen to stimulate TGF-β expression [43] and increase latent TGF-β activation [44] , which would imply them to have adverse effects in CED patients, who display TGF-β1 overactivity. On the other hand, they were found to induce a shift of TGF-β binding from the signalling-capable receptor to the non-signalling receptor [45] [46] [47] , thereby downregulating signalling. Moreover, the glucocorticoid dexamethasone was shown to interfere more downstream in the signalling pathway, thereby inhibiting TGF-β-induced transcription of target genes. [48] Several reports demonstrate the successful treatment of CED patients with the glucocorticoid prednisolone. [ [53] In all cases, there is an improvement of clinical symptoms like pain and fatigue; correction of radiographic abnormalities is documented as well. Of our patient set, 12 patients from nine different families are treated with prednisolone or related drugs (see Table 1 ). For seven of them, information on the effect of treatment was made available. Suffering from lower limb pain, one of the patients from family 1 received high prednisone doses over a two-year period. Onemonth treatments kept her painfree for several months, but pain relapsed in due time. One of the affected children from family 2 was treated with prednisone for one year, starting on a dose of 30 mg/day, which was lowered to 10 mg every second day. Weight, appetite and walking ability increased notably and he complained much less of skeletal pain. Treatment was discontinued because the boy developed aggressive behaviour which was thought to be related. Treatment of the two clinically affected patients from family 3 resulted in an improved mobility and decreased bone pain. However, therapy had to be suspended as the patients became Cushingoid. The symptomatic patient from family 5 benefited from the medication as pain and muscle weakness disappeared, while appetite and vigour increased. For the patients from family 11, low glucocorticoid doses helped to suppress pain. Although it is tempting to speculate that glucocorticoids improve bone pain by suppressing bone formation, the improvement of clinical symptoms to treatment can be very rapid and is therefore unlikely to be due to the suppressive effect on osteoblast function.
Despite these positive reports, long-term glucocorticoid treatment is not advisable, as unfavourable side-effects can occur. For example long-term prednisolone use in children can negatively affect linear growth. [54] Furthermore, spinal osteoporosis as present in two patients from family 3 might be related to the long-term corticosteroid treatment, as spine BMD in two patients from family 4, who were not treated with glucocorticoids, was increased. Therefore, it is important to define the minimal effective dosis. A good starting dose is 1mg/kg/day, but this can and should be lowered during long-term treatment. Deflazacort, a derivative of prednisolone, was reported to have a comparable effect in improving clinical and radiological symptoms, but to give fewer adverse effects, and might therefore form a safer alternative. [55] The use of bisphosphonates in the treatment of CED is disputable. Besides the five patients described here (see Table 1 ), the literature holds very few examples of treatment with these drugs. One report mentions a worsening of bone pain upon therapy with pamidronate [51] , while another patient profited by treatment with the same drug. [56] A patient from family 6 underwent a five-week treatment with weekly pamidronate infusions without amelioration of her symptoms. Likewise, two patients from family 3 did not benefit from a three months intravenous pamidronate treatment. Etidronate treatment of another patient (family 4) even had an adverse effect as it augmented serum alkaline phosphatase levels above normal. Taking into account the fact that bisphosphonates are widely used as antiresorptive drugs in the treatment of osteoporosis -increasing BMD and lowering fracture risk [57] -they do not promise to hold a future as a therapy for CED.
The treatment of one of the patients with calcitonin (family 4) is the first report on the use of this drug in CED therapy. Besides functioning as an analgesic, able to relief bone pain [58] , calcitonin is also known as a potent inhibitor of bone resorption, hence its application in osteoporosis and Paget's Disease of Bone. [59] Consequently, it is unlikely that this drug is a good option to treat CED -although recent in vivo findings point to an additional role of calcitonin as an inhibitor of bone formation. [60] Application in the patient described here was discontinued as no improvements were apparent.
Other medication applied includes non-steroid anti-inflammatory drugs (NSAIDs) such as aspirin. Although these drugs can alleviate pain, they are not effective in improving bone changes.
An alternative to medication is surgery. Bone overgrowth in the diaphyses with concomitant narrowing of the medullar canal and modelling defects can be alleviated by reaming of the medullar canal [61] [62] or osteotomy (this report; families 3 and 24). Orbital decompression to remove bone encroachment on the optic nerves has been applied in one case (family 10). It has to be noted however that since the disorder is progressive, symptoms will recur in due time.
In the future, gene therapy might be considered as an additional way to cure CED patients. Based on their capacity of sequestering the mature peptide, decorin, biglycan, α 2 -macroglobulin, soluble β-glycan, α 2 -HS glycoprotein/fetuin, anti-TGF-β monoclonal antibodies or a soluble, inactive type II receptor could be considered as possible drugs. [63] [64] [65] [66] Alternatively, inhibitors of downstream signaling molecules could be applied. In all cases, it should be taken into account that TGF-β1 is implicated in a myriad of functions in the body, increasing the risk for unwanted side effects upon systemic administration of such a 'quencher'. Consequently, local application -confined to bone and muscle tissue -is preferable.
Diagnosis and genetic counselling
As clinical and radiological variability is extensive, molecular analysis can provide an additional resource to diagnose patients correctly. Family 5 presents a nice example of the complementarity of clinical, radiological and molecular findings. In a previous publication on this family, dating from 1994, the mother and maternal grandfather of a severely affected girl had been diagnosed with CED. [67] The mother did not show any radiological abnormalities, but scintigraphy demonstrated a focus of increased tracer uptake at the base of the skull. The grandfather was found to have marked fusiform enlargement and cortical thickening along the medial borders of the long bones, despite being symptom-free. Linkage analysis in the 19q13 region -previously defined as containing the CED gene [12] -excluded this locus. Although this could point to genetic heterogeneity, mutation analysis of TGFB1 disclosed a Y81H missense mutation in the girl. The presence of the same mutation in family 6 confirmed this to be the diseasecausing mutation. The absence of the mutation in the mother of the girl and in other family members at the maternal side suggested this to be a de novo mutation. Alternatively, the mutation could be segregating in the paternal branch of the pedigree. Mutation analysis learned that the latter was the case as the mutation was detected in the father and paternal grandmother of the girl. Radiographic analyses of both individuals showed no signs of the disorder (no scintigraphies were taken). Although radiographs of the maternal grandfather diagnosed him with CED, bone scintigrams were considered normal. Unfortunately, no additional data on this individual were made available for further diagnosis. Furthermore, increased tracer uptake at the skull base as seen in the mother is a common phenomenon in the normal population and cannot be used as a diagnostic marker of CED. This example shows that the combination of clinical, radiological, scintigraphic and molecular data might be mandatory for a definite diagnosis of this disorder.
Interestingly, four of the five patients demonstrating radiological non-penetrance belong to the two families (5 and 6) carrying the Y81H mutation. Upon comparison, it appears that the patients with the Y81H variant have a statistically significant lower penetrance. Of nine patients with the Y81H mutation, only five (56%) show signs of the disorder. On the contrary, the genotype is penetrant in 77 out of 78 patients with a mutation different from the Y81H variant (99%) (p-value < 0.02). Although this could imply that the Y81H variant is not the disease-causing mutation, earlier functional experiments provided evidence to the contrary. Overexpression of the mutant protein in a cell culture system showed that the protein is less efficiently secreted than the wild-type protein, but far more capable of initiating the TGF-β signaling pathway. [17] The extreme phenotypic variability of the disorder and occasional lack of penetrance render genetic counselling problematic, in particular dealing with the issue of prenatal diagnosis. A healthy carrier can give birth to a severely affected child. On the other hand, a severe affection status of the parent does not necessarily imply a negative disease course in the child. In the most severely affected patients, normal way of living becomes difficult, as they are in constant pain and are bedridden. As there is no possibility to predict the disease outcome, not even on the basis of the nature of the mutation, abortion upon prenatal testing can be contemplated. To our knowledge, only one affected parent from our series of patients considered prenatal diagnosis and obtained it following an indepth discussion with a genetic counsellor.
In conclusion, the survey of a large collection of families suffering from this rare bone disorder aids to define the full spectrum and frequency of the various CED phenotypes and can be of assistance to clinicians both for diagnostic and therapeutic purposes.
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Figure 2
Whole body bone scintigraphy of a patient from family 13 demonstrating the symmetrical distribution of the disease. Increased tracer uptake is visible in the diaphyseal portion of the long bones of the femora, lower legs, humeri and forearms, clavicles and frontal bones. There is minor increased uptake at the parietal and occipital bones. Also note slight valgus deformity of the knees. Table 1 Overview of clinical, radiological, scintigraphic and molecular data on patients from the 24 families. * This family has been described by Janssens et al. [12] . † This family has been described by Makita et al. [9] . ‡ These families have been described by Campos-Xavier et al. [10] . § This family has been described by Wallace et al. [11] . ?: data not available; ND: not determined; /: absent; ↑ : increased; ↓ : decreased; BMD: bone mineral density; GC: glucocorticoids; BP: bisphophonates; NSAIDs: non-steroid antiinflammatory drugs; ESR: erythrocyte sedimentation rate; CRP: C reactive protein.
Table 2
Overview of mutations reported in CED families thusfar.
